Keverprazan

Developed for: Helicobacter pylori infectious disease
Investigated by: Nanjing First Hospital, Nanjing Medical University · Eighth Affiliated Hospital, Sun Yat-sen University · Foshan Fuxing Chancheng Central Hospital · Guangzhou First People's Hospital · Key Laboratory for Gastrointestinal Diseases of Gansu Province · Longgang District People's Hospital of Shenzhen
+4 more
· Second Affiliated Hospital, School of Medicine, Zhejiang University · Shenzhen Baoan District People's Hospital · Sixth Affiliated Hospital, Sun Yat-sen University · The Seventh Affiliated Hospital of Sun Yat-sen University

2025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT06777732	Mar → Sep 2025 overdue	Helicobacter pylori infectious disease	Nanjing First Hospital, Nanjing Medical University	Not yet recruiting	No outcome recorded
Phase 31 trial
Phase 3	NCT06760065	Jan 2025 → Dec 2027 expected	Helicobacter pylori infectious disease	Sixth Affiliated Hospital, Sun Yat-sen University	Not yet recruiting	No outcome recorded
Phase 42 trials
Phase 4	NCT06412640	Jun → Dec 2024	Helicobacter pylori infectious disease	Nanjing First Hospital, Nanjing Medical University	Unknown	No outcome recorded
Phase 4	NCT07122024	Feb 2024 → Aug 2025 overdue	Helicobacter pylori infectious disease	Second Affiliated Hospital, School of Medicine, Zhejiang University	Recruiting	No outcome recorded
Phase not applicable1 trial
—	NCT06851468	Mar → Nov 2025	Helicobacter pylori infectious disease	Key Laboratory for Gastrointestinal Diseases of Gansu Province	Completed	No outcome recorded
Comparator or background therapy1 trial
Phase 3	NCT06734260 Comparator	Sep 2024 → Nov 2025 overdue	—	Eighth Affiliated Hospital, Sun Yat-sen University	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 6 sources stand behind the page.

Field	Value	Cited text
Known as	Keverprazan	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07122024 ↗ 5 NCT06412640 ↗ NCT06851468 ↗ NCT06760065 ↗ NCT06734260 ↗ NCT06777732 ↗
Known as	Keverprazan Hydrochloride	“Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral” NCT06734260 ↗
Action	Inhibit	“stronger and longer inhibition effect on gastric acid compared with PPIs” NCT06734260 ↗
Route	Oral	“Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral” NCT06734260 ↗